Primary aldosteronism in general practice: organ damage, epidemiology and treatment

Recruiting

• Conditions: 10003216; high blood pressure; primary aldosteronism; 10082206; 10001353

• Registration Number: NL-OMON37681
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 1100

Inclusion Criteria

Newly diagnosed hypertensive patients in general practice

Exclusion Criteria

Use of antihypertensive medication
Heart failure class II, III or IV (according to the New York Heart Association)
Pregnancy or breastfeeding

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Part 1: Prevalence of primary aldosteronism in newly diagnosed hypertensive<br /><br>patients in Dutch general practice<br /><br><br /><br>Part 2: Difference in cardiorenovascular damage in patients with versus without<br /><br>PA, based on a composite of the following parameters:<br /><br>- Left ventricular mass index in g/m2<br /><br>- Intima-media thickness of carotid artery in mm<br /><br>- Pulse wave velocity in m/s<br /><br>- Central aortic blood pressure in mmHg<br /><br>- Flow-mediated dilation in %<br /><br>- Albuminuria in mg albumin per mmol creatinin<br /><br><br /><br>Part 3: Difference in reduction of daytime systolic ABPM in patients with<br /><br>normokalemic PA versus patients with essential hypertension in a<br /><br>standardized treatment regimen during conventional antihypertensive therapy</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Part 2: to observe differences in<br /><br>• Serum potassium<br /><br>• Low density lipoprotein<br /><br>• Total cholesterol to high density lipoprotein ratio<br /><br><br /><br>Part 3: to observe differences in<br /><br>• Reduction of daytime systolic ABPM in patients with PA versus patients with<br /><br>essential hypertension in a standardized treatment regimen during<br /><br>spironolactone (or eplerenone)<br /><br>• Serum potassium response using conventional antihypertensive medication<br /><br>• Adverse effects using conventional antihypertensive medication<br /><br>• Serum potassium response using spironolactone (or eplerenone)<br /><br>• Adverse effects using spironolactone (or eplerenone)</p><br>